Drug Trial Radar · NCT07298434
Study of VYD2311 for the Prevention of COVID-19
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,770
Planned (sponsor's estimate)
Start
Jan 8, 2026
Primary completion
Aug 2026
Study completion Aug 2026
Sponsor
- Lead sponsor
- Invivyd, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 100 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adults and adolescents at least 12 years old. Participants in this study will be given a "study drug" that will be either VYD2311 or placebo. The study drug will be given as a shot into the muscle in the participant's upper thigh or upper arm once a month with a total of 3 shots during the study. This study will help researchers see how well VYD2311 works to prevent COVID-19 during the 90 days after the first shot. The study will also look at the safety and tolerability of VYD2311, how the study drug is processed by the body (pharmacokinetics), how the immune system reacts to the study drug (immunogenicity), and how well VYD2311 can block the virus from infecting cells (neutralization). To do these tests, your blood will be drawn at certain times during the study.
Conditions
- COVID-19
Interventions
VYD2311-SDDrug
VYD2311-SD (single-dose arm): Intramuscular injection dosing on Day 1 with VYD2311 and Intramuscular injection dosing Placebo (normal saline) on Day 30 and Day 60
VYD2311-MDDrug
VYD2311-MD (multi-dose): Intramuscular injection dosing on Day 1, Day 30, and Day 60 with VYD2311
PlaceboDrug
Intramuscular injection dosing on Day 1, Day 30, and Day 60 with Placebo (Normal Saline)
Primary outcomes
What the sponsor says the trial is designed to measure.
- RT-PCR-confirmed symptomatic COVID-19 through Day 90Time frame: 90 days
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Invivyd Investigative Site
Long Beach, California
Inviviyd Investigative Site
San Diego, California
Invivyd Investigative Site
Orlando, Florida
Invivyd Investigative Site
Hinesville, Georgia
Invivyd Investigative Site
Melrose Park, Illinois
Invivyd Investigative Site
Lenexa, Kansas
Invivyd Investigative Site
Silver Spring, Maryland
Invivyd Investigative Site
Burlington, Massachusetts
Invivyd Investigative Site
Southfield, Michigan
Invivyd Investigative Site
Maplewood, Minnesota
Invivyd Investigative Site
Independence, Missouri
Invivyd Investigative Site
Jersey City, New Jersey
Invivyd Investigative Site
The Bronx, New York
Invivyd Investigative Site
Philadelphia, Pennsylvania
Invivyd Investigative Site
Myrtle Beach, South Carolina
Invivyd Investigative Site
Goodlettsville, Tennessee
Invivyd Investigative Site
Houston, Texas
Invivyd Investigative Site
Houston-2, Texas
Invivyd Investigative Site
Irving, Texas
Invivyd Investigative Site
Sugar Land, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.